NO20022649L - Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer - Google Patents

Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer

Info

Publication number: NO20022649L
Authority: NO; Norway
Prior art keywords: dihydropyrimidines; heterocyclic; potassium channel; channel inhibitors; inhibitors
Prior art date: 1999-12-06

Application number

NO20022649A

Other languages

English (en)

Other versions

NO323588B1 (no

NO20022649D0 (no

Inventor

Karnail S Atwal

Wayne D Vaccaro

John Lloyd

Heather Finlay

Lin Yan

Rao S Bhandaru

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-06

Filing date

2002-06-05

Publication date

2002-06-06

2002-06-05 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-06-05 Publication of NO20022649D0 publication Critical patent/NO20022649D0/no

2002-06-06 Publication of NO20022649L publication Critical patent/NO20022649L/no

2007-06-11 Publication of NO323588B1 publication Critical patent/NO323588B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

NO20022649A 1999-12-06 2002-06-05 Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer samt anvendelse derav og farmasoytisk preparat. NO323588B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16909199P	1999-12-06	1999-12-06
US23603700P	2000-09-28	2000-09-28
PCT/US2000/032785 WO2001040231A1 (en)	1999-12-06	2000-12-04	Heterocyclic dihydropyrimidines as potassium channel inhibitors

Publications (3)

Publication Number	Publication Date
NO20022649D0 NO20022649D0 (no)	2002-06-05
NO20022649L true NO20022649L (no)	2002-06-06
NO323588B1 NO323588B1 (no)	2007-06-11

Family

ID=26864749

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022649A NO323588B1 (no)	1999-12-06	2002-06-05	Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer samt anvendelse derav og farmasoytisk preparat.

Country Status (25)

Country	Link
US (3)	US6706720B2 (no)
EP (1)	EP1237891B1 (no)
JP (1)	JP2004507442A (no)
KR (1)	KR20020060255A (no)
CN (1)	CN1407985A (no)
AR (1)	AR029457A1 (no)
AT (1)	ATE526329T1 (no)
AU (1)	AU781862B2 (no)
BR (1)	BR0016166A (no)
CA (1)	CA2393809C (no)
CO (1)	CO5570109A1 (no)
CZ (1)	CZ20021949A3 (no)
HK (1)	HK1048808A1 (no)
HU (1)	HUP0301834A3 (no)
IL (2)	IL149473A0 (no)
MX (1)	MXPA02005533A (no)
MY (1)	MY125533A (no)
NO (1)	NO323588B1 (no)
NZ (1)	NZ518663A (no)
PE (1)	PE20011029A1 (no)
PL (1)	PL364926A1 (no)
RU (1)	RU2296766C2 (no)
TW (1)	TWI291465B (no)
UY (1)	UY26472A1 (no)
WO (1)	WO2001040231A1 (no)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901691D0 (en)	1999-01-26	1999-03-17	Cerebrus Ltd	Chemical compounds
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
BR0112038A (pt) *	2000-06-30	2003-04-01	Wyeth Corp	Triazolopirimidinas substituìdas como agentes anticâncer
MXPA03005770A (es) *	2000-12-25	2003-09-10	Sankyo Co	Composiciones medicinales que contienen aspirina.
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
JP2004534026A (ja) *	2001-05-05	2004-11-11	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
HUP0400048A3 (en)	2001-05-05	2008-10-28	Smithkline Beecham Plc	N-aroyl cyclic amines and pharmaceutical compositions containing them
US7139344B2 (en) *	2001-05-16	2006-11-21	Lexmark International, Inc.	Method and apparatus for effecting synchronous pulse generation for use in variable speed serial communications
EP1399441B1 (en) *	2001-06-28	2006-07-05	Smithkline Beecham Plc	N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) *	2001-06-28	2001-08-22	Smithkline Beecham Plc	Compounds
IL160693A0 (en)	2001-09-21	2004-08-31	Bristol Myers Squibb Co	Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1506196B1 (en) *	2001-11-01	2012-01-18	Icagen, Inc.	Pyrazolopyrimidines as sodium channel inhibitors
US7435824B2 (en)	2002-04-19	2008-10-14	Bristol-Myers Squibb Company	Prodrugs of potassium channel inhibitors
WO2003101993A1 (en) *	2002-06-04	2003-12-11	Neogenesis Pharmaceuticals, Inc.	Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7169771B2 (en)	2003-02-06	2007-01-30	Bristol-Myers Squibb Company	Thiazolyl-based compounds useful as kinase inhibitors
US6846836B2 (en)	2003-04-18	2005-01-25	Bristol-Myers Squibb Company	N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
ATE482200T1 (de)	2003-05-01	2010-10-15	Bristol Myers Squibb Co	Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
GB0315950D0 (en)	2003-06-11	2003-08-13	Xention Discovery Ltd	Compounds
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
CA2543707A1 (en) *	2003-10-31	2005-05-19	Takeda Pharmaceutical Company Limited	Nitrogen-containing fused heterocyclic compounds
RU2256450C1 (ru) *	2004-03-04	2005-07-20	Лазебник Леонид Борисович	Способ лечения фибрилляции предсердий
US7550499B2 (en)	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
GB0412986D0 (en)	2004-06-10	2004-07-14	Xention Discovery Ltd	Compounds
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7754755B2 (en) *	2004-09-23	2010-07-13	Bristol-Myers Squibb Company	Inhibitors of 15-lipoxygenase
US7429611B2 (en) *	2004-09-23	2008-09-30	Bristol-Myers Squibb Company	Indole inhibitors of 15-lipoxygenase
US20060128726A1 (en) *	2004-11-24	2006-06-15	Xuebao Wang	Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
US7576212B2 (en)	2004-12-09	2009-08-18	Xention Limited	Thieno[2,3-B] pyridines as potassium channel inhibitors
EP1841504B1 (en)	2005-01-13	2014-11-19	Bristol-Myers Squibb Company	Substituted biaryl compounds as factor xia inhibitors
KR20070100894A (ko)	2005-01-19	2007-10-12	브리스톨-마이어스 스큅 컴퍼니	혈전색전성 장애 치료용 ｐ2ｙ1 수용체 억제제로서의2-페녹시-ｎ-(1,3,4-티아디졸-2-일)피리딘-3-아민 유도체및 관련 화합물
US20060178388A1 (en) *	2005-02-04	2006-08-10	Wrobleski Stephen T	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1888534B1 (en)	2005-06-06	2017-07-26	Intra-Cellular Therapies, Inc.	Organic compounds
MX2007016501A (es)	2005-06-27	2008-03-06	Squibb Bristol Myers Co	Antagonistas heterociclicos n-enlazados del receptor de p2y1, utiles en el tratamiento de condiciones tromboticas.
ATE502924T1 (de)	2005-06-27	2011-04-15	Bristol Myers Squibb Co	Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
WO2007002634A1 (en)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7700620B2 (en)	2005-06-27	2010-04-20	Bristol-Myers Squibb Company	C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7473784B2 (en) *	2005-08-01	2009-01-06	Bristol-Myers Squibb Company	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US20080214570A1 (en) *	2005-08-08	2008-09-04	Astrazeneca Ab	Therapeutic Agents
US7534804B2 (en) *	2005-08-24	2009-05-19	Bristol-Myers Squibb Company	Benzoxazole inhibitors of 15-lipoxygenase
WO2007027454A1 (en)	2005-08-30	2007-03-08	Bristol-Myers Squibb Company	Heterocyclic dihydropyrimidine compounds
ES2273599B1 (es) *	2005-10-14	2008-06-01	Universidad De Barcelona	Compuestos para el tratamiento de la fibrilacion auricular.
GB0525164D0 (en)	2005-12-09	2006-01-18	Xention Discovery Ltd	Compounds
AU2007210013B2 (en) *	2006-02-01	2011-08-18	Merck Sharp & Dohme Corp.	Potassium channel inhibitors
CA2651519A1 (en)	2006-06-06	2007-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
AU2007260984A1 (en) *	2006-06-20	2007-12-27	Wyeth	Kv1.5 potassium channel inhibitors
TW200812962A (en) *	2006-07-12	2008-03-16	Astrazeneca Ab	New compounds I/418
WO2009010810A2 (en) *	2006-08-07	2009-01-22	Wockhardt Limited	Cardiovascular combinations comprising ace and hmg-co-a inhibitors
US7960569B2 (en)	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP5837278B2 (ja)	2006-12-05	2015-12-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
EP2148871A1 (en)	2007-04-23	2010-02-03	Sanofi-Aventis	Quinoline-carboxamide derivatives as p2y12 antagonists
KR101509829B1 (ko) *	2007-05-02	2015-04-06	포톨라 파마슈티컬스, 인코포레이티드	혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
US20090012103A1 (en) *	2007-07-05	2009-01-08	Matthew Abelman	Substituted heterocyclic compounds
WO2009006580A1 (en) *	2007-07-05	2009-01-08	Cv Therapeutics, Inc.	Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
EP2178373B1 (en) *	2007-08-17	2013-01-23	Icagen, Inc.	Heterocycles as potassium channel modulators
US8431608B2 (en)	2007-08-17	2013-04-30	Icagen Inc.	Heterocycles as potassium channel modulators
JP5701608B2 (ja) *	2007-12-06	2015-04-15	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
CA2709187A1 (en) *	2007-12-19	2009-06-25	Wyeth Llc	4-imidazolidinones as kv1.5 potassium channel inhibitors
WO2009079624A1 (en) *	2007-12-19	2009-06-25	Wyeth	4-imidazolidinones as kv1.5 potassium channel inhibitors
MX2010006033A (es)	2007-12-20	2010-07-16	Bayer Schering Pharma Ag	4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso.
EP2238128B1 (en)	2007-12-26	2012-08-22	Sanofi	Heterocyclic pyrazole-carboxamides as p2y12 antagonists
TW201008930A (en)	2008-05-19	2010-03-01	Schering Corp	Heterocyclic compounds as factor IXa inhibitors
RU2376307C1 (ru) *	2008-05-27	2009-12-20	Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук	4-((Z)-4'-ГИДРОКСИБУТЕН-2'-ИЛ)-2-R-6-ФЕНИЛ-1,2,4-ТРИАЗОЛО[5,1-c][1,2,4]ТРИАЗИН-7-ОНЫ
GB2461037A (en) *	2008-06-17	2009-12-23	Elias Bouras	A method of treating alopecia using a composition comprising a cardiac glycoside
RU2463070C1 (ru) *	2008-07-23	2012-10-10	Хэбэй Илин Медицин Рисёч Инститьют Ко., Лтд.	Фармацевтическая композиция для регуляции калиевых каналов в клетке сердечной мышцы, способ ее получения и ее применения
GB0815782D0 (en)	2008-08-29	2008-10-08	Xention Ltd	Novel potassium channel blockers
GB0815781D0 (en)	2008-08-29	2008-10-08	Xention Ltd	Novel potassium channel blockers
GB0815784D0 (en)	2008-08-29	2008-10-08	Xention Ltd	Novel potassium channel blockers
PE20110834A1 (es)	2008-12-06	2011-12-14	Intra Cellular Therapies Inc	DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
AU2009322900A1 (en) *	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
BRPI0922700A2 (pt) *	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
EP2358723B1 (en)	2008-12-06	2015-05-13	Intra-Cellular Therapies, Inc.	4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
US8536159B2 (en)	2008-12-06	2013-09-17	Intra-Cellular Therapies, Inc.	Organic compounds
GEP20146046B (en)	2008-12-06	2014-02-25	Intracellular Therapies Inc	Organic compounds
DE102009004197A1 (de)	2009-01-09	2010-07-15	Bayer Schering Pharma Aktiengesellschaft	Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
WO2010132127A1 (en)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Organic compounds
GB0909672D0 (en)	2009-06-04	2009-07-22	Xention Discovery Ltd	Compounds
GB0909671D0 (en)	2009-06-04	2009-07-22	Xention Discovery Ltd	Compounds
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
HRP20140786T1 (hr) *	2009-07-02	2014-11-07	Sanofi	DERIVATI 6,7,8,9-TETRAHIDROPIRIMIDO[1,2-a]PIRIMIDIN-4-ONA, NJIHOVO DOBIVANJE I NJIHOVA FARMACEUTSKA UPOTREBA
US8828997B2 (en) *	2009-07-02	2014-09-09	Sanofi	2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof
EP2462123B1 (en)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
EP2576551A4 (en)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
EP2590657A4 (en)	2010-05-31	2014-02-12	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
EP2575817A4 (en)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
US8609669B2 (en)	2010-11-16	2013-12-17	Abbvie Inc.	Potassium channel modulators
JP5925809B2 (ja) *	2011-01-26	2016-05-25	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用
GB201105659D0 (en)	2011-04-01	2011-05-18	Xention Ltd	Compounds
WO2012158399A1 (en)	2011-05-13	2012-11-22	Abbott Laboratories	Condensed 2 - carbamoylpyridazinones as potassium channel modulators
US10561656B2 (en)	2011-06-10	2020-02-18	Intra-Cellular Therapies, Inc.	Organic compounds
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
NO3175985T3 (no)	2011-07-01	2018-04-28
BR112014011254A2 (pt)	2011-11-11	2017-05-16	Pfizer	2-tiopirimidinonas
AU2013203252B2 (en)	2012-01-27	2015-08-20	Gilead Sciences, Inc.	Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2013130808A1 (en)	2012-02-29	2013-09-06	D.E. Shaw Research, Llc	Methods for screening voltage gated proteins
SG11201405477XA (en)	2012-04-06	2014-11-27	Pfizer	Diacylglycerol acyltransferase 2 inhibitors
WO2013166037A1 (en)	2012-05-01	2013-11-07	The Trustees Of Columbia University In The City Of New York	Non-retinoid antagonists for treatment of eye disorders
CN107501275B (zh)	2012-12-07	2019-11-22	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物
EP2956141A4 (en)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	NEW USES
WO2014151959A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968304B1 (en)	2013-03-14	2018-10-10	The Trustees of Columbia University in the City of New York	4-phenylpiperidines, their preparation and use
WO2014151936A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydropyrrolopyrroles, their preparation and use
EP2968303B1 (en)	2013-03-14	2018-07-04	The Trustees of Columbia University in the City of New York	Octahydrocyclopentapyrroles, their preparation and use
JP2016512239A (ja)	2013-03-15	2016-04-25	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用な化合物
DK2970279T3 (da)	2013-03-15	2020-11-30	Intra Cellular Therapies Inc	Organiske forbindelser
EP2970288A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
ES2871327T3 (es)	2013-03-15	2021-10-28	Intra Cellular Therapies Inc	Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP
US9663519B2 (en)	2013-03-15	2017-05-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
ES2665153T3 (es)	2013-10-09	2018-04-24	Pfizer Inc.	Antagonistas del receptor EP3 de prostaglandina
RU2537295C1 (ru) *	2013-11-01	2014-12-27	Общество с ограниченной ответственностью "Уральский центр биофармацевтических технологий"	4-(2-ГИДРОКСИЭТОКСИ)МЕТИЛ)-5-МЕТИЛ-2-МЕТИЛМЕРКАПТО-1,2,4-ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7(4Н)-ОН - ВЕЩЕСТВО, ОБЛАДАЮЩЕЕ ПРОТИВОВИРУСНЫМ ДЕЙСТВИЕМ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ПРОТИВ ВОЗБУДИТЕЛЯ ЛИХОРАДКИ ЗАПАДНОГО НИЛА
PT3077397T (pt)	2013-12-06	2020-01-22	Vertex Pharma	Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
PE20161368A1 (es)	2014-03-17	2016-12-25	Pfizer	Inhibidores de diacilglicerol aciltranferasa 2
ME03599B (me)	2014-04-04	2020-07-20	Pfizer	Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitora irak4
EP3131897B8 (en)	2014-04-16	2022-08-03	Merck Sharp & Dohme LLC	Factor ixa inhibitors
SG11201608943VA (en)	2014-04-30	2016-11-29	Univ Columbia	Substituted 4-phenylpiperidines, their preparaiton and use
JP6568111B2 (ja)	2014-06-05	2019-08-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物の放射性標識された誘導体、この化合物およびその異なる固体形態の調製
HRP20191375T1 (hr)	2014-06-17	2019-11-01	Vertex Pharma	Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
ES2732442T3 (es)	2014-06-20	2019-11-22	Intra Cellular Therapies Inc	Compuestos orgánicos
EP3177627B1 (en)	2014-08-07	2019-07-24	Intra-Cellular Therapies, Inc.	Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
EP3725789B1 (en)	2014-09-17	2022-03-09	Intra-Cellular Therapies, Inc.	7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
JP2017538769A (ja)	2014-12-22	2017-12-28	ファイザー・インク	プロスタグランジンｅｐ３受容体の拮抗薬
CN107635972A (zh)	2015-03-18	2018-01-26	拜耳制药股份公司	用于生产(4s)‑4‑[4‑氰基‑2‑(甲基磺酰基)苯基]‑3，6‑二甲基‑2‑氧代‑1‑[3‑(三氟甲基)苯基]‑1，2，3，4‑四氢嘧啶‑5‑甲腈的方法
AU2016257179A1 (en)	2015-05-05	2017-11-02	Pfizer Inc.	2-thiopyrimidinones
WO2016193844A1 (en)	2015-05-29	2016-12-08	Pfizer Inc.	Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
CR20170572A (es)	2015-06-17	2018-03-20	Pfizer	Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
WO2016203335A1 (en)	2015-06-18	2016-12-22	Pfizer Inc.	Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017025849A1 (en)	2015-08-13	2017-02-16	Pfizer Inc.	Bicyclic-fused heteroaryl or aryl compounds
AU2016311376B2 (en)	2015-08-27	2018-10-04	Pfizer Inc.	Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
WO2017037567A1 (en)	2015-09-03	2017-03-09	Pfizer Inc.	Regulators of frataxin
RU2768621C1 (ru)	2015-09-30	2022-03-24	Вертекс Фармасьютикалз Инкорпорейтед	Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
ES2871251T3 (es)	2015-12-29	2021-10-28	Pfizer	3-Azabiciclo[3.1.0]Hexanos sustituidos como inhibidores de la cetohexocinasa
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
ES2953467T3 (es) *	2016-04-15	2023-11-13	Elanco Animal Health Gmbh	Derivados de pirazolopirimidina
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
CA3030381A1 (en)	2016-07-14	2018-01-18	Pfizer Inc.	Pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
WO2018049417A1 (en)	2016-09-12	2018-03-15	Intra-Cellular Therapies, Inc.	Novel uses
TWI800498B (zh) *	2016-12-21	2023-05-01	義大利商吉斯藥品公司	作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
JOP20190284A1 (ar) *	2017-06-14	2019-12-11	Bayer Pharma AG	مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2019133445A1 (en)	2017-12-28	2019-07-04	Inception Ibd, Inc.	Aminothiazoles as inhibitors of vanin-1
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
MX2021002428A (es)	2018-08-31	2023-01-02	Pfizer	Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
WO2020102575A1 (en)	2018-11-16	2020-05-22	Inception Ibd, Inc.	Heterocyclic aminothiazoles and uses thereof
ES3039586T3 (en)	2019-05-20	2025-10-22	Pfizer	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110229161A (zh) *	2019-07-12	2019-09-13	江苏建筑职业技术学院	四氮唑并[1,5-a]嘧啶衍生物的溶剂热合成法
JP7612672B2 (ja)	2019-09-03	2025-01-14	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規化合物
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease
CA3189771A1 (en)	2020-07-22	2022-01-27	Janssen Pharmaceutica Nv	Compounds useful as factor xia inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
CA3214112A1 (en) *	2021-03-30	2022-10-06	Fabrizio Giordanetto	Aryl heterocyclic compounds as kv1.3 potassium shaker channel blockers
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US12286429B2 (en)	2021-07-22	2025-04-29	Janssen Pharmaceutica Nv	5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2023204629A1 (ko) *	2022-04-20	2023-10-26	일동제약(주)	Cftr 활성제 화합물을 제조하는 방법 및 이에 사용되는 중간체
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL130088C (no) *	1960-03-14
GB1031088A (en) *	1964-04-16	1966-05-25	Hoechst Ag	Benzenesulphonyl-ureas and process for their manufacture
US3423414A (en)	1966-01-13	1969-01-21	Ciba Geigy Corp	Pyrazolopyridines
HU173438B (hu)	1975-11-27	1979-05-28	Chinoin Gyogyszer Es Vegyeszet	Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
BE863525A (fr)	1977-02-14	1978-07-31	Bristol Myers Co	Heterocyclopyrimidines
CA1095906A (en) *	1977-02-14	1981-02-17	Davis L. Temple, Jr.	Heterocyclopyrimidines, compositions and therapeutic process
AU557300B2 (en)	1982-03-16	1986-12-18	Farmitalia Carlo Erba S.P.A.	Substituted 1h-pyrazolo(1,5-alpha)pyrimidines and processes for their preparation
JPS59116243A (ja)	1982-12-23	1984-07-05	Mitsui Toatsu Chem Inc	２―アリールエチルエーテル誘導体およびチオエーテル誘導体の製造方法
EP0125204A1 (de) *	1983-04-12	1984-11-14	Ciba-Geigy Ag	3-Phenoxybenzyl-(2-phenyl-2,2-alkylen-äthyl)-äther und -thioäther, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4918074A (en) *	1984-03-12	1990-04-17	Yoshitomi Pharmaceutical Industries, Ltd.	Polyazaheterocycle compounds
JPS60246387A (ja)	1984-05-22	1985-12-06	Yoshitomi Pharmaceut Ind Ltd	ジヒドロイミダゾ〔１，２−ａ〕ピリミジン誘導体
JPS60193990A (ja) *	1984-03-12	1985-10-02	Yoshitomi Pharmaceut Ind Ltd	新規なポリアザ複素環誘導体
JPS61227584A (ja)	1985-03-15	1986-10-09	Yoshitomi Pharmaceut Ind Ltd	ポリアザ複素環誘導体
EP0217142A3 (en) *	1985-09-30	1988-01-07	Yoshitomi Pharmaceutical Industries, Ltd.	A polyazaheterocyclic compound
US4755594A (en) *	1986-01-31	1988-07-05	Warner-Lambert Company	N6 -substituted adenosines
US4746656A (en)	1986-07-21	1988-05-24	E. R. Squibb & Sons, Inc.	1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives
JPS6360985A (ja)	1986-08-08	1988-03-17	Yoshitomi Pharmaceut Ind Ltd	４，７−ジヒドロピラゾロ〔１，５−ａ〕ピリミジン誘導体
JPS63107983A (ja)	1986-09-25	1988-05-12	Yoshitomi Pharmaceut Ind Ltd	トリアゾロピリミジン誘導体
JPS63243029A (ja) *	1987-03-30	1988-10-07	Yoshitomi Pharmaceut Ind Ltd	循環器系疾患治療薬
DE3724366A1 (de) *	1987-07-23	1989-02-02	Hoechst Ag	Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
US4950585A (en)	1987-08-18	1990-08-21	Konica Corporation	Coupler for photographic use
JPH01271751A (ja)	1988-04-23	1989-10-30	Konica Corp	新規な写真用カプラーを含有するハロゲン化銀カラー写真感光材料
GB8905130D0 (en)	1989-03-07	1989-04-19	Pfizer Ltd	Therapeutic agents
DE3922232A1 (de) *	1989-07-06	1991-01-17	Basf Ag	Fungizide guanidine
WO1993014083A1 (en)	1992-01-09	1993-07-22	Janssen Pharmaceutica N.V.	Pharmaceutically active substituted benzimidazole derivatives
JPH05289267A (ja)	1992-04-07	1993-11-05	Fuji Photo Film Co Ltd	ハロゲン化銀カラー写真感光材料
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5900415A (en) *	1994-11-07	1999-05-04	Pfizer Inc.	Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
DE4443891A1 (de) *	1994-12-09	1996-06-13	Bayer Ag	Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9500691D0 (en) *	1995-01-13	1995-03-08	Smithkline Beecham Plc	Compounds
US5670504A (en) *	1995-02-23	1997-09-23	Merck & Co. Inc.	2,6-diaryl pyridazinones with immunosuppressant activity
JPH08301871A (ja) *	1995-05-01	1996-11-19	Takeda Chem Ind Ltd	縮合複素環化合物およびその製造法
US5631282A (en) *	1995-06-07	1997-05-20	Merck & Co., Inc.	Triterpenes
US5679705A (en) *	1995-10-31	1997-10-21	Merck & Co., Inc.	Triterpene derivatives with immunosuppressant activity
US5696156A (en) *	1995-10-31	1997-12-09	Merck & Co. Inc.	Triterpene derivatives with immunosuppressant activity
FR2746309B1 (fr)	1996-03-22	1998-04-17	Oreal	Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
US5935945A (en)	1996-10-31	1999-08-10	Merck & Co., Inc.	Methods of treating or preventing cardiac arrhythmia
US5969017A (en)	1996-10-31	1999-10-19	Merck & Co., Inc.	Methods of treating or preventing cardiac arrhythmia
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP2894445B2 (ja)	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
US5952363A (en) *	1997-03-04	1999-09-14	Novo Nordisk A/S	Pyrrolidine compounds useful in the treatment of diabetes
US6455550B1 (en) *	1997-08-22	2002-09-24	Hoffmann-La Roche Inc.	N-alkanoylphenylalanine derivatives
ID26984A (id)	1998-07-06	2001-02-22	Bristol Myers Squibb Co	Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
AU754204B2 (en)	1998-09-01	2002-11-07	Bristol-Myers Squibb Company	Potassium channel inhibitors and method
US6632836B1 (en) *	1998-10-30	2003-10-14	Merck & Co., Inc.	Carbocyclic potassium channel inhibitors
JP3583314B2 (ja) *	1999-06-17	2004-11-04	矢崎総業株式会社	端子構造
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
GB0012214D0 (en) *	2000-05-19	2000-07-12	Merck Sharp & Dohme	Therapeutic agents
DE10030375A1 (de) *	2000-06-21	2002-01-03	Bayer Ag	Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
EP1320522B8 (en)	2000-09-19	2006-02-01	Moses Lee	Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins
GB0114867D0 (en) *	2001-06-18	2001-08-08	Merck Sharp & Dohme	Therapeutic agents
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function

2000
- 2000-11-21 MY MYPI20005460A patent/MY125533A/en unknown
- 2000-11-29 TW TW089125386A patent/TWI291465B/zh not_active IP Right Cessation
- 2000-12-04 EP EP00980930A patent/EP1237891B1/en not_active Expired - Lifetime
- 2000-12-04 CZ CZ20021949A patent/CZ20021949A3/cs unknown
- 2000-12-04 CN CN00816751A patent/CN1407985A/zh active Pending
- 2000-12-04 JP JP2001540986A patent/JP2004507442A/ja active Pending
- 2000-12-04 AT AT00980930T patent/ATE526329T1/de not_active IP Right Cessation
- 2000-12-04 HK HK03100853.3A patent/HK1048808A1/zh unknown
- 2000-12-04 CA CA002393809A patent/CA2393809C/en not_active Expired - Fee Related
- 2000-12-04 MX MXPA02005533A patent/MXPA02005533A/es active IP Right Grant
- 2000-12-04 RU RU2002118622/04A patent/RU2296766C2/ru not_active IP Right Cessation
- 2000-12-04 NZ NZ518663A patent/NZ518663A/en unknown
- 2000-12-04 BR BR0016166-7A patent/BR0016166A/pt not_active Application Discontinuation
- 2000-12-04 KR KR1020027007194A patent/KR20020060255A/ko not_active Ceased
- 2000-12-04 PL PL00364926A patent/PL364926A1/xx not_active Application Discontinuation
- 2000-12-04 WO PCT/US2000/032785 patent/WO2001040231A1/en not_active Ceased
- 2000-12-04 IL IL14947300A patent/IL149473A0/xx unknown
- 2000-12-04 HU HU0301834A patent/HUP0301834A3/hu unknown
- 2000-12-04 AU AU18127/01A patent/AU781862B2/en not_active Ceased
- 2000-12-05 US US09/729,731 patent/US6706720B2/en not_active Expired - Lifetime
- 2000-12-06 CO CO00092974A patent/CO5570109A1/es not_active Application Discontinuation
- 2000-12-06 AR ARP000106468A patent/AR029457A1/es unknown
- 2000-12-06 PE PE2000001303A patent/PE20011029A1/es not_active Application Discontinuation
- 2000-12-07 UY UY26472A patent/UY26472A1/es not_active Application Discontinuation
2002
- 2002-05-05 IL IL149473A patent/IL149473A/en not_active IP Right Cessation
- 2002-06-05 NO NO20022649A patent/NO323588B1/no not_active IP Right Cessation
2003
- 2003-09-12 US US10/660,878 patent/US7157451B2/en not_active Expired - Lifetime
2006
- 2006-12-06 US US11/634,574 patent/US7541362B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1407985A (zh)	2003-04-02
EP1237891B1 (en)	2011-09-28
US6706720B2 (en)	2004-03-16
HUP0301834A2 (hu)	2003-09-29
NZ518663A (en)	2004-11-26
US20070099899A1 (en)	2007-05-03
ATE526329T1 (de)	2011-10-15
CO5570109A1 (es)	2005-10-31
IL149473A (en)	2009-05-04
HK1048808A1 (zh)	2003-04-17
AU1812701A (en)	2001-06-12
AR029457A1 (es)	2003-07-02
MY125533A (en)	2006-08-30
TWI291465B (en)	2007-12-21
RU2002118622A (ru)	2004-01-10
US7541362B2 (en)	2009-06-02
AU781862B2 (en)	2005-06-16
US20030022890A1 (en)	2003-01-30
EP1237891A1 (en)	2002-09-11
RU2296766C2 (ru)	2007-04-10
US7157451B2 (en)	2007-01-02
WO2001040231A1 (en)	2001-06-07
HUP0301834A3 (en)	2004-11-29
IL149473A0 (en)	2002-11-10
US20040063687A1 (en)	2004-04-01
UY26472A1 (es)	2001-07-31
CZ20021949A3 (cs)	2003-03-12
JP2004507442A (ja)	2004-03-11
CA2393809A1 (en)	2001-06-07
KR20020060255A (ko)	2002-07-16
PE20011029A1 (es)	2001-12-02
MXPA02005533A (es)	2002-10-31
PL364926A1 (en)	2004-12-27
NO323588B1 (no)	2007-06-11
CA2393809C (en)	2009-11-17
BR0016166A (pt)	2003-06-24
NO20022649D0 (no)	2002-06-05

Publication	Publication Date	Title
NO20022649L (no)	2002-06-06	Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
NO20014642L (no)	2001-11-28	Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20021239L (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
CY2016042I2 (el)	2017-03-15	Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20022139L (no)	2002-05-03	Kinazolinderivater som VEGF inhibitorer
PT1181017E (pt)	2003-06-30	Inibidores de metaloproteases
NO20031006L (no)	2003-03-04	Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
NO20014483D0 (no)	2001-09-14	Aminderivater som proteaseinhibitorer
NO20015065D0 (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
DE60008527D1 (de)	2004-04-01	Zellproliferation inhibitoren
NO20024997D0 (no)	2002-10-17	2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
PT1194404E (pt)	2006-08-31	Inibidores de aspartil-protease
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1228073T3 (da)	2003-11-03	Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20014875D0 (no)	2001-10-08	Promedikamenter for trombin inhibitorer
DE60024101D1 (de)	2005-12-22	Enzyminhibitoren
DK1147119T3 (da)	2004-01-19	2,3-O-isopropylidenderivater af monosaccharider som celleadhæsionsinhibitorer
IS7833A (is)	2005-05-02	Efnasambönd með sameinaða heteróhringi
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
DK1222193T3 (da)	2003-12-01	Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20035206L (no)	2003-11-24	Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees